Denosumab in the Treatment of Osteoporosis: 10&#xA0;Years Later: A Narrative Review

Osteoporosis

Invasive Oral Procedures and Events in Women With Postmenopausal Osteoporosis Treated With Denosumab for up to 10 Years

J Clin Endocrinol Metab.

Watts NB, Grbic JT, Binkley N, Papapoulos S, Butler PW, Yin X, Tierney A, Wagman RB, McClung M

doi: 10.1210/jc.2018-01965.

Osteoporosis

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians

Ann Intern Med.

Qaseem A, Forciea MA, McLean RM, Denberg TD; Clinical Guidelines Committee of the American College of Physicians

doi: 10.7326/M15-1361.

Osteoporosis

Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis

Expert Opin Drug Saf.

Fontalis A, Kenanidis E, Prousali E, Potoupnis M, Tsiridis E

doi: 10.1080/

Osteoporosis

Adherence to osteoporosis pharmacotherapy one year after osteoporotic fracture - a Swiss trauma center secondary prevention project

Swiss Med Wkly.

Morell S, Hemmeler C, Amsler F, Gross T

doi: 10.4414/smw.2017.14451

Osteoporosis

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis

Osteoporos Int.

Biver E, Calmy A, Aubry-Rozier B, Birkhäuser M, Bischoff-Ferrari HA, Ferrari S, Frey D, Kressig RW, Lamy O, Lippuner K, Suhm N, Meier C

doi: 10.1007/s00198-018-4794-0.

Osteoporosis

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

Lancet Diabetes Endocrinol.

Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF

doi: 10.1016/

Psoriasis

Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review

Arch Dermatol Res.

Florek AG, Wang CJ, Armstrong AW

doi: 10.1007/s00403-018-1808-x.

COMMENTED

Osteoporosis

Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial

Arthritis Rheumatol.

Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF

doi: 10.1002/art.40874.

COMMENTED

Osteoporosis

Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density

Osteoporos Int.

Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R

doi: 10.1007/s00198-018-4460-6.

Dermatology · Immunology · Rheumatology

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review

Related content

Invasive Oral Procedures and Events in Women With Postmenopausal Osteoporosis Treated With Denosumab for up to 10 Years

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians

Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis

Adherence to osteoporosis pharmacotherapy one year after osteoporotic fracture - a Swiss trauma center secondary prevention project

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review

Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial

Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density